Lipocine Swings to Near-Breakeven as Q3 Revenue Jumps to $2.3M
LPCN is trading near its 52-week low of $1.36 (6.6% above the low) on light trading volume (0.1× avg).
Summary
Q3 revenue hit $2.3M versus $115K a year earlier, and the net loss narrowed to $0.7M from $3.2M, or 8 cents a share. The revenue is not commercial traction: $2.1M came from license and collaboration revenue, with TLANDO royalties only $190K. Cash and marketable securities stood at $21.5M on September 30 and roughly $28.5M as of November 4, up from $14.9M at December 31, 2025 — a meaningful cushion for a company this size, though the ATM remains open. The operating story is still LPCN 1154: the BLOOM Phase 3 study is expected to enroll about 120 patients, and FDA feedback indicated one positive, well-controlled Phase 3 trial would support an NDA. That trial result, not this quarter's license line, is what determines the equity.
At the time of this announcement, LPCN was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.9M. The 52-week trading range was $1.36 to $12.37. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.